January 22, 2018 — Baxter International Inc. announced the U.S. Food and Drug Administration (FDA) approval of Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin). Bivalirudin is a specific and direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), a common non-surgical procedure to treat blocked or narrowed blood vessels in the heart.
Bivalirudin will use Baxter's proprietary frozen GALAXY container technology, a non-PVC and non-DEHP system specifically designed to create a ready-to-use format for unstable molecules. Premixed versions of commonly prescribed drugs help simplify the preparation process and can avoid potential errors that may occur when medications are compounded. Compounding is the process of combining different ingredients in specific quantities to fill individualized prescriptions.
Baxter's premixed medications are manufactured to current Good Manufacturing Practice (cGMP) regulations established and monitored by the FDA. Bivalirudin is expected to launch in the United States in early 2018 in two commonly prescribed dosage forms and strengths: 250 mg of bivalirudin per 50 mL (5 mg/mL) and 500 mg of bivalirudin per 100 mL (5 mg/mL).
For more information: www.baxter.com
Related Bivalirudin Content
No Benefit to Prolonging Bivalirudin after PCI
Meta-Analysis Evaluates the Effect of Post-PCI Bivalirudin on Adverse Clinical Events
No Difference in Adverse Events When Comparing Anticoagulants
Bivalirudin, Heparin Achieve Similar Anticoagulation Results in TAVR Patients
Advantages and Disadvantages of Novel Oral Anticoagulants
Questions Remain on DAPT Prolongation
August 28, 2023 
